INmune Bio (NASDAQ:INMB) Earns Outperform Rating from Analysts at Raymond James
Raymond James assumed coverage on shares of INmune Bio (NASDAQ:INMB – Free Report) in a research report released on Friday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $18.00 target price on the stock. Separately, Scotiabank started coverage on shares of INmune Bio in a research note on Thursday, August 22nd. […]
More Stories
Bank of America Co. (NYSE:BAC) Major Shareholder Sells $154,725,779.52 in Stock
Bank of America Co. (NYSE:BAC) major shareholder Berkshire Hathaway Inc sold 3,915,126 shares of the stock in a transaction on...
Insider Selling: Royal Bank of Canada (TSE:RY) Senior Officer Sells C$2,855,150.00 in Stock
Royal Bank of Canada (TSE:RY – Get Free Report) (NYSE:RY) Senior Officer Douglas Antony Guzman sold 17,000 shares of the...
Insider Selling: Toll Brothers, Inc. (NYSE:TOL) CEO Sells 50,000 Shares of Stock
Toll Brothers, Inc. (NYSE:TOL – Get Free Report) CEO Douglas C. Jr. Yearley sold 50,000 shares of Toll Brothers stock...
Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $2,298,000.00 in Stock
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) insider Andrew Hollman Meyer sold 50,000 shares of the stock in a...
Critical Analysis: Amazon.com (NASDAQ:AMZN) & Beyond (NYSE:BYON)
Amazon.com (NASDAQ:AMZN – Get Free Report) and Beyond (NYSE:BYON – Get Free Report) are both retail/wholesale companies, but which is...
Short Interest in U.S. Global Investors, Inc. (NASDAQ:GROW) Rises By 24.6%
U.S. Global Investors, Inc. (NASDAQ:GROW – Get Free Report) saw a large growth in short interest in September. As of...